Get the Stockscreener App
0.9399
6.01%
-0.0601
After Hours:
.91
-0.0299
-3.18%
Marker Therapeutics Inc stock is traded at $0.9399, with a volume of 2.21M.
It is down -6.01% in the last 24 hours and down -39.75% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.00
Open:
$0.99
24h Volume:
2.21M
Relative Volume:
1.18
Market Cap:
$12.16M
Revenue:
-
Net Income/Loss:
$-9.70M
P/E Ratio:
-0.8545
EPS:
-1.1
Net Cash Flow:
$-8.57M
1W Performance:
-18.97%
1M Performance:
-39.75%
6M Performance:
-38.37%
1Y Performance:
-74.04%
1-Day Range:
$0.92
$1.00
1-Week Range:
$0.92
$1.40
52-Week Range:
$0.92
$5.95
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
0.9399 | 12.94M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Analyzing Marker Therapeutics Inc. with risk reward ratio charts2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study - Insider Monkey
Exit strategy if you’re trapped in Marker Therapeutics Inc.Weekly Stock Summary & Short-Term Trading Opportunity Alerts - Newser
Is Marker Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 News Drivers & Fast Entry Momentum Alerts - Newser
Is Marker Therapeutics Inc. forming a bottoming baseQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
Can trapped investors hope for a rebound in Marker Therapeutics Inc.July 2025 Highlights & AI Forecast Swing Trade Picks - Newser
Marker Therapeutics Inc.’s volatility index tracking explained2025 Institutional Moves & Fast Exit and Entry Strategy Plans - Newser
10 Stocks Losing Big - Insider Monkey
Can you recover from losses in Marker Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - Newser
Will Marker Therapeutics Inc. continue its uptrendOptions Play & Entry Point Confirmation Alerts - Newser
Marker Therapeutics Inc (MRKR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Published on: 2025-08-26 21:38:35 - beatles.ru
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment - Benzinga
Marker Therapeutics shares fall 14.29% intraday after a Phase I clinical update from the APOLLO study. - AInvest
Transcript : Marker Therapeutics, Inc.Special Call - MarketScreener
Marker Therapeutics Faces Major Shift amidst Strategic Challenges - StocksToTrade
Marker Therapeutics’ Shares Leaps: What’s Behind the Rise? - timothysykes.com
Marker Therapeutics stock soars on promising Phase 1 lymphoma study data - Investing.com
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study - MarketScreener
Marker Therapeutics Reports Promising Phase 1 Study Results - TipRanks
Marker Therapeutics : Corporate Presentation - MarketScreener
What earnings revisions data tells us about Marker Therapeutics Inc.2025 Short Interest & Free Growth Oriented Trading Recommendations - Newser
Marker Therapeutics Provides Update on Phase 1 APOLLO Study - GlobeNewswire
66% Response Rate: Marker's Novel T Cell Therapy Shows Promise for CAR-T Resistant Lymphoma Patients - Stock Titan
Published on: 2025-08-26 05:28:09 - Newser
Is it time to cut losses on Marker Therapeutics Inc.Earnings Performance Report & Weekly High Return Stock Forecasts - Newser
Loss Report: What’s the outlook for Marker Therapeutics Inc.’s sectorJuly 2025 Outlook & Breakout Confirmation Trade Signals - theviewers.co.kr
Will earnings trigger a reversal in Marker Therapeutics Inc.Weekly Trend Report & Low Drawdown Momentum Ideas - Newser
Published on: 2025-08-23 15:45:36 - Newser
Can machine learning forecast Marker Therapeutics Inc. recoveryMarket Activity Report & Technical Pattern Based Signals - Newser
What are Marker Therapeutics Inc.’s growth leversJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - theviewers.co.kr
Applying chart zones and confluence areas to Marker Therapeutics Inc.Portfolio Return Report & Real-Time Stock Movement Alerts - Newser
Valuation Update: Will Marker Therapeutics Inc. benefit from rate cutsM&A Rumor & Daily Profit Maximizing Tips - theviewers.co.kr
Chart Analysts Warn of Resistance Near Marker Therapeutics Inc. Price2025 Sector Review & Daily Stock Momentum Reports - beatles.ru
Will Marker Therapeutics Inc. Hold Gains Into CloseMarket Risk Report & Weekly High Return Forecasts - classian.co.kr
Fibonacci Support Holding Strong in Marker Therapeutics Inc.July 2025 Summary & Community Consensus Trade Signals - classian.co.kr
Is Marker Therapeutics Inc. impacted by rising ratesOptions Play & Verified Momentum Stock Alerts - theviewers.co.kr
Analysts Spot Bullish Divergence in Marker Therapeutics Inc.July 2025 WrapUp & Fast Exit and Entry Strategy Plans - beatles.ru
Marker Therapeutics Inc. Stock Approaches Key Moving Average2025 Volatility Report & Weekly Breakout Watchlists - 더경남뉴스
Published on: 2025-08-21 02:07:42 - newsyoung.net
Using Ichimoku Cloud for Marker Therapeutics Inc. technicalsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Momentum divergence signals in Marker Therapeutics Inc. chartJuly 2025 News Drivers & High Conviction Buy Zone Picks - Newser
Watch for Bullish Crossover in Marker Therapeutics Inc.July 2025 Weekly Recap & Community Supported Trade Ideas - Newser
Short interest data insights for Marker Therapeutics Inc.2025 Macro Impact & Low Risk Entry Point Tips - Newser
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):